Литература

  1. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006;13:119–128.
  2. Udelsman R, Chen H. The current management of thyroid cancer. Adv Surg. 1999;33:1–27.
  3. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317–322.
  4. Leenhardt L, Bernier MO, Boin-Pineau MH, Conte Devolx B, Marechaud R, Niccoli-Sire P, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 2004;150:133–139.
  5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.
  6. Brito JP, Al Nofal A, Montori VM, Hay ID, Morris JC. The impact of subclinical disease and mechanism of detection on the rise in thyroid cancer incidence: a population-based study in Olmsted County, Minnesota During 1935 through 2012. Thyroid. 2015;25:999–1007.
  7. Ries LAG, Melbert D, Krapcho M, Bethesda MD. SEER cancer statistics review; 2007: 1975-2005. National Cancer Institute.
  8. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States. JAMA. 2006;295:1973–2002. 2164-7.
  9. Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am. 2009;89:1193–1204.
  10. Zarebczan B, Chen H. Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir. 2010;65: 59–69.
  11. Tuttle RM, Becker DV. The Chernobyl accident and its consequences: update at the millennium. Semin Nucl Med. 2000;30:133–140.
  12. Cetta F, Montalto G, Petracci M, Fusco A. Thyroid cancer and the Chernobyl accident. Are longterm and long distance side effects of fallout radiation greater than estimated Endocrinol Metab. J Clin Endocrinol Metab. 1997;82:2015–2017.
  13. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med. 1991;325:599–605.
  14. Fraker DL. Radiation exposure and other factors that predispose to human thyroid neoplasia. Surg Clin North Am. 1995;75:365–375.
  15. Horn-Ross PL, Morris JS, Lee M. Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. Cancer Epidemiol Biomarkers Prev. 2001;10:979–985.
  16. Knobel M, Medeiros-Neto G. Relevance of iodine intake as a reputed predisposing factor for thyroid cancer. Arq Bras Endocrinol Metabol. 2007; 51:701–712.
  17. Alberti L, Carniti C, Miranda C. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol. 2003;195:168–186.
  18. Fusco A, Chiappetta G, Hui P. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol. 2002;160:2157–2167.
  19. Fugazzola L, Puxeddu E, Avenia N. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006;13:455–464.
  20. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013;98: E1852–E1860.
  21. Nikiforova MN, Lynch RA, Biddinger PW. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88:2318–2326.
  22. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569–580.
  23. Niemeier LA, Kuffner Akatsu H, Song C, Carty SE, Hodak SP, Yip L, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012;118:2069–2077.
  24. Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol. 2013;20:2266–2273.
  25. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010;17: 3294–3300.
  26. Medema RH, Bos JL. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog. 1993;4:615–661.
  27. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21:3226–3235.
  28. Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab. 2008;22: 955–969.
  29. Gianoukakis AG, Giannelli SM, Salameh WA, McPhaul LW. Well differentiated follicular thyroid neoplasia: impact of molecular and technological advances on detection, monitoring and treatment. Mol Cell Endocrinol. 2011;332:9–20.
  30. Ohori NP, Schoedel KE. Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: sources and recommendations. Acta Cytol. 2011;55:492–498.
  31. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95: 1365–1369.
  32. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390–3397.
  33. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092–2098.
  34. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, Hershman JM, Babu V, Blevins TC, et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. Thyroid. 2014;24:1479–1487.
  35. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–690.
  36. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99:E1130–E1136.
  37. Lee S, Hong SW, Shin SJ. Papillary thyroid carcinoma associated with familial adenomatous polyposis: molecular analysis of pathogenesis in a family and review of the literature. Endocr J. 2004;51:317–323.
  38. Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid. 1997;7:107–113.
  39. Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Cancer Control. 2006;13:106–110.
  40. Sippel RS, Caron NR, Clark OH. An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg. 2007;31:924–933.
  41. Bonora E, Tallini G, Romeo G. Genetic predisposition to familial nonmedullary thyroid cancer: an update of molecular findings and state-of-the-art studies. J Oncol. 2010;2010:385206.
  42. Bevan S, Pal T, Greenberg CR. A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1. J Clin Endocrinol Metab. 2001;86:3701–3704.
  43. Bignell GR, Canzian F, Shayeghi M. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet. 1997;61:1123–1130.
  44. McKay JD, Lesueur F, Jonard L. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 2001;69:440–446.
  45. Wang X, Cheng W, Li J, Su A, Wei T, Liu F, et al. Endocrine tumours: familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis. Eur J Endocrinol. 2015;172: R253–R262.
  46. Zhang Q, Yang S, Meng XY, Chen G, Pang RZ. Clinical analysis of familial nonmedullary thyroid carcinoma. World J Surg. 2016;40:570–573.
  47. Mazeh H, Benavidez J, Poehls JL. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one fi ee relative is associated with more aggressive disease. Thyroid. 2012;22:3–8.
  48. Bradly DP, Reddy V, Prinz RA, Guttuso P. Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery. 2009;146: 1099–1104.
  49. From G, Mellemgaard A, Knudsen N. Review of thyroid cancer cases among patients with previous benign thyroid disorders. Thyroid. 2000;10:697–700.
  50. Roti E, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma results of a retrospective study in 243 patients. J Clin Endocrinol Metab. 2006;91:2171–2178.
  51. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007;13:498–512.
  52. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol. 2008;159: 659–673.
  53. Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg. 2011;254: 653–660.
  54. Mazeh H, Chen H. Advances in surgical therapy for thyroid cancer. Nat Rev Endocrinol. 2011;7:581–588.
  55. Lang BH, Chow SM, Lo CY. Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann Surg. 2007;246:114–121.
  56. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414–424.
  57. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin GL 3rd. Surgeon-performed ultrasound in the management of thyroid malignancy. Am Surg. 2004;70:576–580, discussion 80-82.
  58. Shimamoto K, Satake H, Sawaki A, Ishigaki T, Funahashi H, Imai T. Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol. 1998;29:4–10.
  59. Qubain SW, Nakano S, Baba M, Takao S, Aikou T. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery. 2002;131:249–256.
  60. Arturi F, Russo D, Giuffrida D, Ippolito A, Perrotti N, Vigneri R, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab. 1997;82:1638–1641.
  61. Wada N, Suganuma N, Nakayama H. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. Langenbecks Arch Surg. 2007;392: 417–422.
  62. Ito Y, Tomoda C, Uruno T. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. WORLD. 2004;28:498–501.
  63. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically signifi prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106:524–531.
  64. Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71:731–734.
  65. Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33:2370–2375.
  66. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–1095.
  67. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–953.
  68. Hay ID, Bergstralh EJ, Goellner JR. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during through. Surgery. 1993;114:1050–1057, discussion 1057–1058.
  69. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418– 428.
  70. Byar DP, Green SB, Dor P. A prognostic index for thyroid carcinoma. A study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15: 1033–1041.
  71. Sherman SI, Brierley JD, Sperling M. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83:1012–1021.
  72. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manuel. 7th ed. New York: Springer-Verlag; 2010.
  73. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Seer, Bethesda MD Statistics Review; 2005. National Cancer Institute.
  74. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306.
  75. Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM. Follicular thyroid cancer treated at the Mayo Clinic, through: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1991;66:11–22.
  76. Thompson LD, Wieneke JA, Paal E. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer. 2001;91:505–524.
  77. Chen H, Nicol TL, Zeiger MA. Hьrthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg. 1998;227:542–546.
  78. Harness JK, Thompson NW, McLeod MK. Follicular carcinoma of the thyroid gland: trends and treatment. Surgery. 1984;96:972–980.
  79. Phitayakorn R, McHenry CR. Follicular and Hьrthle cell carcinoma of the thyroid gland. Surg Oncol Clin. 2006;15:603–623, ixx.
  80. Zhang YW, Greenblatt DY, Repplinger D. Older age and larger tumor size predict malignancy in Hьrthle cell neoplasms of the thyroid. Ann Surg Oncol. 2008; 15:2842–2846.
  81. Wreesmann VB, Ghossein RA, Patel SG. Genomewide appraisal of thyroid cancer progression. Am J Pathol. 2002;161:1549–1556.
  82. Burman KD, Ringel MD, Wartofsky L. Unusual types of thyroid neoplasms. Endocrinol Metab Clin North Am. 1996;25:49–68.
  83. Wang W, Macapinlac H, Larson SM. [18F]-2-fluoro2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291–2302.
  84. Widder S, Pasieka JL. Primary thyroid lymphomas. Curr Treat Options Oncol. 2004;5:307–313.
  85. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904.
  86. Steele SR, Martin MJ, Mullenix PS, Azarow KS, Andersen CA. The signifi of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg. 2005;140:981–985.
  87. Hagag P, Strauss S, Weiss M. Role of ultrasoundguided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid. 1998;8:989–995.
  88. Leenhardt L, Hejblum G, Franc B, Fediaevsky LD, Delbot T, Le Guillouzic D, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab. 1999;84:24–28.
  89. Nam-Goong IS, Kim HY, Gong G, Lee HK, Hong SJ, Kim WB, et al. Ultrasonography-guided fi aspiration of thyroid incidentaloma: correlation with pathological fi Clin Endocrinol (Oxf). 2004;60: 21–28.
  90. Scheumann GF, Gimm O, Wegener G. Prognostic signifi and surgical management of locoregional lymph node metastases in papillary thyroid cancer. WORLD. 1994;18:559–567.
  91. Belfiore A, Garofalo MR, Giuffrida D. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab. 1990;70:830– 835.
  92. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553–559.
  93. Nagai GR, Pitts WC, Basso L. Scintigraphic hot nodules and thyroid carcinoma. Clin Nucl Med. 1987;12:123–127.
  94. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fi aspiration. J Clin Endocrinol Metab. 2006;91:4295–4301.
  95. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93:809–814.
  96. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of wholebody radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid. 2002;12:37–43.
  97. Doherty GM, Haugen BR, Kloos RT. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214.
  98. Mazzaferri EL, Robbins RJ, Spencer CA. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–1441.
  99. Gharib H, Papini E, Valcavi R. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006;12:63–102.
  100. Brito JP, Ito Y, Miyauchi A, Tuttle RM. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid. 2016;26:144–149.
  101. Crippa S, Mazzucchelli L, Cibas ES, Ali SZ. The Bethesda System for reporting thyroid fineneedle aspiration specimens. Am J Clin Pathol. 2010;134:343–344, author reply 345.
  102. Vriens MR, Sabanci U, Epstein HD. Reliability of fine-needle aspiration in patients with familial nonmedullary thyroid cancer. Thyroid. 1999;9: 1011–1016.
  103. Alexander EK, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab. 2002;87:4924–4927.
  104. Cameci C, Jeffrey RB, McDougall IR. Ultrasoundguided fine-needle aspiration biopsy of thyroid masses. Thyroid. 1998;8:283–289.
  105. Cha YJ, Koo JS. Next-generation sequencing in thyroid cancer. J Transl Med. 2016;14:322.
  106. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(suppl 2): S37–S43.
  107. Hodak SP, Rosenthal DS. Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid. 2013;23:131–134.
  108. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381:1058–1069.
  109. Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, et al. 2013 European Thyroid Association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2:147–159.
  110. Poehls JL, Chen H, Sippel RS. Preoperative ultrasonography findings predict the need for repeated surgery in papillary thyroid cancer. Endocr Pract. 2012;18:403–409.
  111. Luo J, McManus C, Chen H, Sippel RS. Are there predictors of malignancy in patients with multinodular goiter? J Surg Res. 2012;174:207–210.
  112. Sippel RS, Chen H. Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer. Thyroid. 2009;19:1373–1380.
  113. Sippel RS, Elaraj DM, Poder L. Localization of recurrent thyroid cancer using intraoperative ultrasoundguided dye injection. WORLD. 2009;33:434–439.
  114. Al-Azawi D, Mann GB, Judson RT, Miller JA. J. Endocrine surgeon-performed US guided thyroid FNAC is accurate and efficient. World J Surg. 2012;36:1947–1952.
  115. Goldfarb M, Gondek SS, Lew JI. Clinic-based ultrasound can predict malignancy in pediatric thyroid nodules. Thyroid. 2012;22:827–831.
  116. Kim MH, Ko SH. Role of [(18)F]-fluorodeoxy-dglucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy. Thyroid. 2012;22:157–164.
  117. Yip L, Stang MT, Carty SE. Thyroid carcinoma: the surgeon’s perspective. Radiol Clin North Am. 2011;49:463–471, vi.
  118. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214.
  119. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38:68–79.
  120. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011;33:645–649.
  121. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136:1055–1061.
  122. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in lowor high-risk papillary thyroid cancer. Ann Surg Oncol. 2005;12:81–89.
  123. Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151:571–579.
  124. Lang BH, Wong CK. Lobectomy is a more costeffective option than total thyroidectomy for 1 to 4 cm papillary thyroid carcinoma that do not possess clinically recognizable high-risk features. Ann Surg Oncol. 2016;23:3641–3652.
  125. Kluijfhout WP, Pasternak JD, Lim J, Kwon JS, Vriens MR, Clark OH, et al. Frequency of highrisk characteristics requiring total thyroidectomy for 1-4 cm well-differentiated thyroid cancer. Thyroid. 2016;26:820–824.
  126. Pinchot SN, Kunnimalaiyaan M, Sippel RS, Chen H. Medullary thyroid carcinoma: targeted therapies and future directions. J Oncol. 2009;31:1830.
  127. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol. 1997;4:328–333.
  128. Wanebo H, Coburn M, Teates D, Cole B. Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg. 1998;227:912–921.
  129. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg. 1998;133:419–425.
  130. Nguyen K, Dilawari RA. Predictive value of AMES scoring system in selection of extent of surgery in well differentiated carcinoma of thyroid. Am Surg. 1995;61:151–155.
  131. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70: 511–518.
  132. Samaan NA, Schultz PN, Hickey RC. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75:714– 720.
  133. Loh KC, Greenspan FS, Gee L. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997;82:3553–3562.
  134. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97: 418–428.
  135. Shindo M, Wu JC, Park EE, Tanzella F. The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2006;132:650–654.
  136. Eustatia-Rutten CF, Corssmit EP, Biermasz NR. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91: 313–319.
  137. Wada N, Duh QY, Sugino K. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399–407.
  138. Gemsenjager E, Perren A, Seifert B. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg. 2003;197:182–190.
  139. Bardet S, Malville E, Rame JP. Macroscopic lymphnode involvement and neck dissection predict lymphnode recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158:551–560.
  140. Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245:604–610.
  141. Hughes DT, Doherty GM. Central neck dissection for papillary thyroid cancer. Cancer Control. 2011;18:83–88.
  142. Lang BH, Wong KP, Wan KY, Lo CY. Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection. Ann Surg Oncol. 2012;19:1257–1263.
  143. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22:1144–1152.
  144. Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative fi ings predict excellent long-term regional control and survival. Thyroid. 2012;22:347–355.
  145. Gyorki DE, Untch B, Tuttle RM, Shaha AR. Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. Ann Surg Oncol. 2013;20:2285–2289.
  146. Carty SE, Cooper DS, Doherty GM, Duh QY, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19:1153–1158.
  147. Tuttle RM, Ball DW, Byrd D. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8:1228–1274.
  148. Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab. 2008;22:989–1007.
  149. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid. 2000;10:767–778.
  150. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–3676.
  151. Ma C, Xie J, Liu W. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database Syst Rev. 2010;(11):CD008302.
  152. Klubo-Gwiezdzinska J, Burman KD, Nostrand D. Van Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. 2012;22: 310–317.
  153. Jonklaas J, Sarlis NJ, Litofsky D. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229–1242.
  154. Chow SM, Law SC, Au SK. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head Neck. 2002;24:670–677.
  155. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235–1245.
  156. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:457–480, x.
  157. Lamartina L, Durante C, Filetti S, Cooper DS. Lowrisk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab. 2015;100:1748–1761.
  158. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009;19:1043–1048.
  159. Kim HJ, Kim NK, Choi JH, Kim SW, Jin SM, Suh S, et al. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2013;78:614–620.
  160. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998;83:553–559.
  161. Creach KM, Siegel BA, Nussenbaum B, Grigsby PW. Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma. ISRN Endocrinol. 2012;2012:816386.
  162. Brown AP, Chen J, Hitchcock YJ. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504–515.
  163. Iyer NG, Morris LG, Tuttle RM. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117:4439–4446.
  164. Chen AY, Levy L, Goepfert H. The development of breast carcinoma in women with thyroid carcinoma. Cancer. 2001;92:225–231.
  165. Wiklund TA, Blomqvist CP, Raty J. Postirradiation sarcoma. Analysis of a nationwide cancer registry material. Cancer. 1991;68:524–531.
  166. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13:265–271.
  167. Almeida JP, Sanabria AE, Lima EN, Kowalski LP. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck. 2011;33:686–690.
  168. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121:4700–4711.
  169. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97: 4390–4398.
  170. McGriff NJ, Csako G, Gourgiotis L. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34(7–8):554–564.
  171. Brierley JD, Tsang RW. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol. 1999;16:42–49.
  172. Tennvall J, Lundell G, Hallquist A. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols The Swedish Anaplastic Thyroid Cancer Group. Cancer. 1994;74:1348–1354.
  173. Shimaoka K, Schoenfeld DA, DeWys WD. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155–2160.
  174. Williams SD, Birch R, Einhorn LH. Phase, II. evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:405–407.
  175. Higgins MJ, Forastiere A, Marur S. New directions in the systemic treatment of metastatic thyroid cancer. Oncology (Williston Park). 2009;23:768–775.
  176. Kim DW, Jo YS, Jung HS. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/ papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006;91:4070–4076.
  177. Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab. 2010;95:987–993.
  178. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–328.
  179. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–630.
  180. Tuttle RM, Tala H, Shah J. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–1349.
  181. Hay ID. Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract. 2007;13:521– 533.
  182. Lesnik D, Cunnane ME, Zurakowski D, Acar GO, Ecevit C, Mace A, et al. Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. Head Neck. 2014;36:191–202.
  183. Yeh MW, Bauer AJ, Bernet VA, Ferris RL, Loevner LA, Mandel SJ, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid. 2015;25:3–14.
  184. Tufano RP, Clayman G, Heller KS, Inabnet WB, Kebebew E, Shaha A, et al. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid. 2015;25:15–27.
  185. Phelan E, Kamani D, Shin J, Randolph GW. Neural monitored revision thyroid cancer surgery: surgical safety and thyroglobulin response. Otolaryngol Head Neck Surg. 2013;149:47–52.
  186. Urken ML, Milas M, Randolph GW, Tufano R, Bergman D, Bernet V, et al. Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative. Head Neck. 2015;37:605–614.
  187. Heilo A, Sigstad E, Fagerlid KH, Haskjold OI, Groholt KK, Berner A, et al. Effi of ultrasoundguided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab. 2011;96:2750– 2755.
  188. Hay ID, Lee RA, Davidge-Pitts C, Reading CC, Charboneau JW. Long-term outcome of ultrasoundguided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery. 2013;154:1448–1454, discussion 54–55.
  189. Papini E, Bizzarri G, Bianchini A, Valle D, Misischi I, Guglielmi R, et al. Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. J Clin Endocrinol Metab. 2013;98:E92–E97.
  190. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.
  191. Hill CS Jr, Ibanez ML, Samaan NA. Medullary (solid) carcinoma of the thyroid gland: an analysis of the M. D Anderson hospital experience with patients with the tumor its special features and its histogenesis. Medicine (Baltimore). 1973;52:141– 171.
  192. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134–2142.
  193. Kouvaraki MA, Shapiro SE, Fornage BD, EdeikenMonro BS, Sherman SI, Vassilopoulou-Sellin R, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946–954, discussion 54–55.
  194. Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98:3149–3164.
  195. Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist. 2013;18:1093–1100.
  196. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg. 2007;31:1960–1965.
  197. Kaserer K, Scheuba C, Neuhold N, Weinhausel A, Haas OA, Vierhapper H, et al. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol. 2001;25:1245–1251.
  198. Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg. 2002;26:1023–1028.
  199. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13:539–547.
  200. Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775–783.
  201. Williams ED, Brown CL, Doniach I. Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid; 1966.
  202. Szavcsur P, Godeny M, Bajzik G, Lengyel E, Repa I, Tron L, et al. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol. 2005;31:183–190.
  203. Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–4190.
  204. Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fi needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol. 2005;91:56–60.
  205. Bhanot P, Yang J, Schnadig VJ, Logrono R. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature. Diagn Cytopathol. 2007;35:285–292.
  206. Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a metaanalysis. Clin Endocrinol (Oxf). 2015;82:280–285.
  207. Boi F, Maurelli I, Pinna G. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:2115–2118.
  208. Chin WW, Goodman RH, Jacobs JW. Medullary thyroid carcinoma identified by cell-free translation of tumor messenger ribonucleic acid in a patient with a neck mass and the syndrome of ectopic adrenocorticotropin. J Clin Endocrinol Metab. 1981;52:572–575.
  209. Costante G, Meringolo D, Durante C. J. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450–455.
  210. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029–2034.
  211. Machens A, Dralle H. Pretargeted anticarcinoembryonic-antigen radioimmunotherapy for medullary thyroid carcinoma. J Clin Oncol. 2006;24:e37, author reply e38.
  212. de Groot JW, Kema IP, Breukelman H. Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid. 2006;16:1163–1170.
  213. Wells SA Jr, Chi DD, Toshima K. Predictive DNA. Wel testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994;220:237–247, discussion 247250.
  214. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid. 2013;23:50–57.
  215. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011;96:E863–E868.
  216. Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab. 2012;97:E2031–E2035.
  217. Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 2009;100:1777–1783.
  218. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic signifi of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682–687.
  219. Kouvaraki MA, Shapiro SE, Perrier ND. RET proto-oncogene: a review and update of genotypephenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15:531–544.
  220. Ogilvie JB, Kebebew E. Indication and timing of thyroid surgery for patients with hereditary medullary thyroid cancer syndromes. J Natl Compr Canc Netw. 2006;4:139–147.
  221. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229:880–887, discussion 887888.
  222. Greenblatt DY, Elson D, Mack E, Chen H. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg. 2007;30:108–112.
  223. Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery. 2006;139:28–32.
  224. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2655–2663.
  225. Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg. 2007;31:957–968.
  226. Tischler AS, Khan A, DeLellis RA. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353:2817–2818, author reply 2817–2818.
  227. Chen H, Roberts JR, Ball DW. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg. 1998;227:887–895.
  228. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077–6084.
  229. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol. 2007;19:18–23.
  230. Wells SA Jr, Robinson BG, Gagel RF. Wel Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134–141.
  231. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3466–3469.
  232. Langmuir PB, Yver A. Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther. 2012;91:71–80.
  233. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29:2660–2666.
  234. Soon PS, Sidhu SB. Adrenocortical carcinoma. Cancer Treat Res. 2010;153:187–210.
  235. Lafemina J, Brennan MF. Adrenocortical carcinoma: past, present, and future. J Surg Oncol. 2012;106: 586–594.
  236. Bilimoria KY, Shen WT, Elaraj D. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130– 3136.
  237. Icard P, Goudet P, Charpenay C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25: 891–897.
  238. Stojadinovic A, Ghossein RA, Hoos A. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20:941–950.
  239. Michalkiewicz E, Sandrini R, Figueiredo B. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004;22:838–845.
  240. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001;86:4970–4973.
  241. Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373:2336–2346.
  242. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, et al. beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res. 2011;17:328–336.
  243. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607–612.
  244. Barreau O, Assie G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J Clin Endocrinol Metab. 2013;98:E174–E184.
  245. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer. 2007;14:13–28.
  246. Kjellman M, Roshani L, Teh BT. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J Clin Endocrinol Metab. 1999;84:730–735.
  247. Bertherat J, Bertagna X. Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab. 2009;23:261–271.
  248. Wandoloski M, Bussey KJ, Demeure MJ. Adrenocortical cancer. Surg Clin North Am. 2009;89: 1255–1267.
  249. Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011;7:323–335.
  250. Czajka I, Zgliczynski W, Kasperlik-Zaluska A, Cichocki A. [Gynecomasty as a first sign of adrenal carcinoma—case report]. Endokrynol Pol. 2005;56: 940–944.
  251. Stewart JN, Flageole H, Kavan P. A surgical approach to adrenocortical tumors in children: the mainstay of treatment. J Pediatr Surg. 2004;39:759–763.
  252. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:273–289.
  253. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356:601–610.
  254. Copeland PM. The incidentally discovered adrenal mass. Ann Surg. 1984;199:116–122.
  255. Grumbach MM, Biller BM, Braunstein GD. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med. 2003;138: 424–429.
  256. Petersenn S, Richter PA, Broemel T, Ritter CO, Deutschbein T, Beil FU, et al. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol. 2015;172:415–422.
  257. Pena CS, Boland GW, Hahn PF. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology. 2000;217:798–802.
  258. Young WF Jr. Conventional imaging in adrenocortical carcinoma: update and perspectives. Horm Cancer. 2011;2:341–347.
  259. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, Blake MA, Hahn PF, et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011;259:117–126.
  260. Gust L, Taieb D, Beliard A, Barlier A, Morange I, de Micco C, et al. Preoperative 18F-FDG uptake is strongly correlated with malignancy, Weiss score, and molecular markers of aggressiveness in adrenal cortical tumors. World J Surg. 2012;36:1406– 1410.
  261. Hahner S, Sundin A. Metomidate-based imaging of adrenal masses. Horm Cancer. 2011;2:348–353.
  262. Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, Verburg FA, et al. Functional characterization of adrenal lesions using [123I]IMTO-SPECT/ CT. J Clin Endocrinol Metab. 2013;98:1508–1518.
  263. Kreissl MC, Schirbel A, Fassnacht M, Haenscheid H, Verburg FA, Bock S, et al. [(1)(2)(3)I]Iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:2755–2764.
  264. Balasubramaniam S, Fojo T. Practical considerations in the evaluation and management of adrenocortical cancer. Semin Oncol. 2010;37:619–626.
  265. Dworakowska D, Drabarek A, Wenzel I, Babinska A, Swiatkowska-Stodulska R, Sworczak K. Adrenocortical

cancer (ACC)—literature overview and own experience. Endokrynol Pol. 2014;65:492–502.

  1. Brix D, Allolio B, Fenske W. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58:609–615.
  2. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12:667–680.
  3. Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255:363–369.
  4. Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, et al. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156:3895–3908.
  5. Terzolo M, Angeli A, Fassnacht M. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–2380.
  6. Grubbs EG, Callender GG, Xing Y. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17:263–270.
  7. Baudin E, Leboulleux S, Al Ghuzlan A. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer. 2011;2: 363–371.
  8. Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2008;15:221–226.
  9. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6:386–394.
  10. Fassnacht M, Terzolo M, Allolio B. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–2197.
  11. Fassnacht M, Hahner S, Polat B. Effi of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:4501–4504.
  12. Ho J, Turkbey B, Edgerly M, Alimchandani M, Quezado M, Camphausen K, et al. Role of radiotherapy in adrenocortical carcinoma. Cancer J. 2013;19:288–294.
  13. Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:192–197.
  14. Hermsen IG, Groenen YE, Dercksen MW, Theuws J, Haak HR. Response to radiation therapy in adrenocortical carcinoma. J Endocrinol Invest. 2010;33: 712–714.
  15. Sabolch A, Feng M, Griffi K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and defi e radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011;80:1477–1484.
  16. Polat B, Fassnacht M, Pfreundner L. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115: 2816–2823.
  17. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91:2027–2037.
  18. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a doubleblind, randomised, phase 3 study. Lancet Oncol. 2015;16:426–435.
  19. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719–726.
  20. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95:4925–4932.
  21. Harari A, Inabnet WB 3rd. Malignant pheochromocytoma a review. Am J Surg. 2011;201:700–708.
  22. Grogan RH, Mitmaker EJ, Duh QY. Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control. 2011;18:104– 112.
  23. Zarnegar R, Kebebew E, Duh QY, Clark OH. Malignant pheochromocytoma. Surg Oncol Clin. 2006;15:555–571.
  24. Adjalle R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009;41:687–696.
  25. Kantorovich V, King KS, Pacak K. SDH-related pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2010;24:415–424.
  26. Neumann HP, Bausch B, McWhinney SR. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459–1466.
  27. Neumann HP, Pawlu C, Peczkowska M. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943–951.
  28. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC press; 2004.
  29. Adler JT, Meyer-Rochow GY, Chen H. Pheochromocytoma: current approaches and future directions. Oncologist. 2008;13:779–793.
  30. Baguet JP, Hammer L, Mazzuco TL. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150:681–686.
  31. Beuschlein F. Adrenal incidentalomas: presentation and clinical work-up. Horm Res. 2007;68(suppl 5): 191–194.
  32. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med. 2008; 132:1272–1284.
  33. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14:569–585.
  34. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011;29:2049–2060.
  35. Walther MM, Reiter R, Keiser HR. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol. 1999;162: 659–664.
  36. Pomares FJ, Canas R, Rodriguez JM. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf ). 1998;48:195–200.
  37. Guller U, Turek J, Eubanks S. Detecting pheochromocytoma: defining the most sensitive test. Ann Surg. 2006;243:102–107.
  38. Taylor RL, Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clin Chem. 2002;48:533–539.
  39. Chen H, Sippel RS, O’Dorisio MS. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010; 39:775–783.
  40. Greenblatt DY, Shenker Y, Chen H. The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma. Ann Surg Oncol. 2008;15:900–905.
  41. Ohta S, Lai EW, Pang AL. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer. 2005;114:139–143.
  42. Strong VE, Kennedy T, Al-Ahmadie H. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery. 2008;143:759–768.
  43. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Clin Pathol. 2002;26:551–566.
  44. Zografos GN, Farfaras A, Vasiliadis G. Laparoscopic resection of large adrenal tumors. JSLS. 2010;14: 364–368.
  45. Zografos GN, Vasiliadis G, Farfaras AN. Laparoscopic surgery for malignant adrenal tumors. JSLS. 2009;13:196–202.
  46. Adler JT, Chen H, Schaefer S, Sippel RS. What is the added benefit of cervical ultrasound to (99m) Tc-sestamibi scanning in primary hyperparathyroidism? Ann Surg Oncol. 2011;18:2907–2911.
  47. Kinney MA, Warner ME, vanHeerden JA. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg. 2000;91:1118–1123.
  48. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf). 2001;55:47–60.
  49. Rutherford MA, Rankin AJ, Yates TM, Mark PB, Perry CG, Reed NS, et al. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre. QJM. 2015;108:361–368.
  50. Huang H, Abraham J, Hung E. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113:2020–2028.
  51. Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;81:642–651.
  52. Harari A, Inabnet WB 3rd. Malignant pheochromocytoma: a review. Am J Surg. 2011;201:700–708.
  53. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52:334–340.
  54. Reisch N, Peczkowska M, Januszewicz A, Neumann HP. Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens. 2006;24:2331-2339.
  55. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012;97:4040– 4050.
  56. Szalat A, Fraenkel M, Doviner V, Salmon A, Gross DJ. Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine. 2011;39: 160–166.
  57. Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107:659–664.
  58. Andersen KF, Altaf R, Krarup-Hansen A. Malignant pheochromocytomas and paragangliomas—the importance of a multidisciplinary approach. Cancer Treat Rev. 2011;37:111–119.
  59. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3:92–102.
  60. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954;16:363–371.
  61. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142:709–723, discussion 724–728.
  62. Lulu DJ, Corcoran TE, Andre M. Familial endocrine adenomatosis with associated ZollingerEllison syndrome. Wermers syndrome. Am J Surg. 1968;115:695–701.
  63. Marx SJ. Multiple endocrine neoplasia type 12002.
  64. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990–3011.
  65. Schussheim DH, Skarulis MC, Agarwal SK. Multiple endocrine neoplasia type 1: new clinical and basic fi Trends Endocrinol Metab. 2001;12:173–178.
  66. Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med. 1990;322:723–727.
  67. Akerstrom G, Stalberg P. Surgical management of MEN-1 andstate of the art. Surg Clin North Am. 2009;89(2):1047–1068.
  68. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore). 2004;83:43–83.
  69. Rubinstein WS. Endocrine cancer predisposition syndromes: hereditary paraganglioma, multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2, and hereditary thyroid cancer. Hematol Oncol Clin North Am. 2010;24:907– 937.
  70. Brandi ML, Gagel RF, Angeli A. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–5671.
  71. Akerstrom G, Johansson H, Grama D. Surgical treatment of endocrine pancreatic lesions in MEN-1. Acta Oncol. 1991;30:541–545.
  72. Sheppard BC, Norton JA, Doppman JL, Maton PN, Gardner JD, Jensen RT. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery. 1989;106:1108–1117, discussion 17–18.
  73. Doherty GM. Multiple endocrine neoplasia type 1. J Surg Oncol. 2005;89:143–150.
  74. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med. 1998;243: 495–500.
  75. Hausman MS Jr, Thompson NW, Gauger PG, Doherty GM. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery. 2004;136:1205–1211.
  76. Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery. 1991;110:998–1004, discussion -5.
  77. Schimke RN, Hartmann WH. Familial amyloidproducing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity. Ann Intern Med. 1965;63:1027–1039.
  78. Bergholm U, Adami HO, Telenius-Berg M. Incidence of sporadic and familial medullary thyroid carcinoma in Sweden through. A nationwide study in 126 patients Swedish Group. Acta Oncol. 1990;29:9–15.
  79. Callender GG, Rich TA, Perrier ND. Multiple endocrine neoplasia syndromes. Surg Clin North Am. 2008;88:863–895, viii.
  80. Vasen HF, van Raue F, der Feltz M. The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Arch Intern Med. 1992;152:1250–1252.
  81. Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, et al. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013;98:E1813–E1819.
  82. Webb TA, Sheps SG, Carney JA. Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrine neoplasia, type 2. Am J Surg Pathol. 1980;4:121–126.
  83. Machens A, Lorenz K, Dralle H. Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. J Clin Endocrinol Metab. 2013;98:E336–E345.
  84. Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3’ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene. 1995;11:2039– 2045.
  85. Mulligan LM, Marsh DJ, Robinson BG. Genotypephenotype correlation in multiple endocrine neoplasia type 2: report of the International Consortium. J Intern Med. 1995;238:343–346.
  86. Hofstra RM, Landsvater RM, Ceccherini I. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367: 375–376.
  87. Kloos RT, Eng C, Evans DB. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565–612.
  88. Wells SA Jr, Dilley WG, Farndon JA, Leight GS, Baylin SB. Early diagnosis and treatment of medullary thyroid carcinoma. Arch Intern Med. 1985;145: 1248–1252.
  89. Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q, et al. Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg. 2007;246: 815–821.
  90. Miccoli P, Minuto MN, Ugolini C, Molinaro E, Basolo F, Berti P, et al. Clinically unpredicТаблица prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer. 2007;14:1099–1105.
  91. Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid. 2001;11: 637–645.
  92. Yip L, Cote GJ, Shapiro SE. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003;138:409–416, discussion 416.
  93. Yip L, Lee JE, Shapiro SE. Surgical management of hereditary pheochromocytoma. J Am Coll Surg. 2004;198:525–534, discussion 534–535.
  94. Lee JE, Curley SA, Gagel RF. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery. 1996;120:1064–1070, discussion 1070–1071.
  95. Obendorfer S. Karzinoide tumoren des dunndarms. Frankf Z Pathol. 1907;1:426–430.
  96. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.
  97. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959.
  98. Alessandro M, Mariani P, Lomanto D. Serum neuron-specific enolase in diagnosis and follow-up of gastrointestinal neuroendocrine tumors. Tumour Biol. 1992;13(5–6):352–357.
  99. Schurmann G, Raeth U, Wiedenmann B. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg. 1992;16:697–701, discussion 701–702.
  100. Rindi G. The E. guidelines: the new TNM classification system. Tumori. 2010;96:806–809.
  101. Rindi G, Kloppel G, Alhman H. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.
  102. Rindi G, Kloppel G, Couvelard A. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–762.
  103. Pahlavan PS, Kanthan R. Goblet cell carcinoid of the appendix. World J Surg Oncol. 2005;3:36.
  104. Gould VE, Linnoila RI, Memoli VA, Warren WH. Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest. 1983;49:519–537.
  105. Schein P. C. B. editor. Decision Making in Oncology; 1988.
  106. Deacon AC. The measurement of 5-hydroxyindoleacetic acid in urine. Ann Clin Biochem. 1994;31(Pt 3):215–232.
  107. Nuttall KL, Pingree SS. The incidence of elevations in urine 5-hydroxyindoleacetic acid. Ann Clin Lab Sci. 1998;28:167–174.
  108. Feldman JM, Lee EM. Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid. Am JClin Nutr. 1985;42:639–643.
  109. Moertel CG. Karnofsky Memorial Lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502–1522.
  110. Tellez MR, Mamikunian G, O’Dorisio TM, Vinik AI, Woltering EA. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas. 2013;42:405–410.
  111. Ardill JE, Armstrong L, Smye M, Doherty R, McCance DR, Johnston BT. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A. QJM. 2016;109:111–115.
  112. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18(suppl 1):S17–S25.
  113. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer. 2007;14:473–482.
  114. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25:1967–1973.
  115. Reidy-Lagunes DL, Gollub MJ, Saltz LB. Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? J Clin Oncol. 2011; 29:e74–e75.
  116. Ganeshan D, Bhosale P, Yang T, Kundra V. Imaging features of carcinoid tumors of the gastrointestinal tract. AJR Am J Roentgenol. 2013;201:773–786.
  117. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70–78.
  118. Sippel RS, Chen H. Carcinoid tumors. Surg Oncol Clin. 2006;15:463–478.
  119. Kvols LK, Brown ML, Connor MK. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology. 1993;187:129– 133.
  120. Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34:588– 596.
  121. Thorson A, Biorck G, Bjorkman G, Waldenstrom J, Heart J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J. 1954;47:795–817.
  122. Pernow B, Waldenstrom J. Paroxysmal flushing and other symptoms caused by 5-hydroxytryptamine and histamine in patients with malignant tumours. Lancet. 1954;951:267.
  123. Oates JA, Melmon K, Sjoerdsma A. Release of a kinin peptide in the carcinoid syndrome. Lancet. 1964;1:514–517.
  124. Oates JA, Pettinger WA, Doctor RB. Evidence for the release of bradykinin in carcinoid syndrome. J Clin Invest. 1966;45:173–178.
  125. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Clin Oncol. 2005;89:151–160.
  126. Richter G, Stockmann F, Conlon JM, Creutzfeldt W. Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology. 1986;91:612–618.
  127. Adamson AR, Grahame-Smith DG, Peart WS, Starr M. Pharmacological blockade of carcinoid flushing provoked by catecholamines and alcohol. Lancet. 1969;2:293–297.
  128. Robertson JI, Peart WS, Andrews TM. The mechanism of facial flushes in the carcinoid syndrome. Q J Med. 1962;31:103–123.
  129. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol. 1983;1:727–740.
  130. Roberts LJ 2nd, Marney SR Jr, Oates JA. Blockade of the fl associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists. Evidence for an important role of H2 receptors in human vasculature. N Engl J Med. 1979;300: 236–238.
  131. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol. 2008;101:378–381.
  132. Roberts WC, Sjoerdsma A. The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease). Am J Med. 1964;36:5–34.
  133. Lundin L. Carcinoid heart disease. A cardiologists viewpoint. Acta Oncol. 1991;30:499–502.
  134. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008;102:938–942.
  135. Denney WD, Kemp WE Jr, Anthony LB. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol. 1998;32:1017– 1022.
  136. Korse CM, Taal BG, de Groot CA. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol. 2009;27:4293–4299.
  137. Thompson GB, van Heerden JA Jr, Martin JK. Carcinoid tumors of the gastrointestinal tract: presentation, management, and prognosis. Surgery. 1985;98:1054–1063.
  138. Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer. 1968;21: 270–278.
  139. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95:135–156.
  140. Chen T, Yao LQ, Xu MD, Zhang YQ, Chen WF, Shi Q, et al. Efficacy and safety of endoscopic submucosal dissection for colorectal carcinoids. Clin Gastroenterol Hepatol. 2016;14:575–581.
  141. Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008;13:1255–1269.
  142. Kim MK, Warner RR, Roayaie S, Harpaz N, Ward SC, Itzkowitz S, et al. Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. J Clin Oncol. 2013;31: 3776–3781.
  143. Edge SB, Byrd DR, Compton CC, New S, et al, eds. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 7th ed. 2010:181.
  144. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89:471–476.
  145. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117:3332–3341.
  146. Landerholm K, Zar N, Andersson RE, Falkmer SE, Jarhult J. Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg. 2011;98:1617–1624.
  147. Chen H, Hardacre JM, Uzar A. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? Coll Surg. 1998;187:88–92, discussion 92–93.
  148. Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17:3129–3136.
  149. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control. 2002;9:67–79.

414a. Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16(10):2892–2902.

414b. Rossi RE, Burroughs AK, Caplin ME. Liver transplantation for unresecТаблица neuroendocrine tumor liver metastases. Ann Surg Oncol. 2014;21(7): 2398–2405.

  1. Rusthoven KE, Kavanagh BD, Cardenes H. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–1578.
  2. Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315: 663–666.
  3. Frolich JC, Bloomgarden ZT, Oates JA. The carcinoid fl Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med. 1978;299:1055–1057.
  4. Rubin J, Ajani J, Schirmer W. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600–606.
  5. Grosman I, Simon D. Potential gastrointestinal uses of somatostatin and its synthetic analogue octreotide. Am J Gastroenterol. 1990;85:1061–1072.
  6. Kvols LK, Moertel CG, Connell MJ. Treatment of the malignant carcinoid syndrome. Evaluation of a longacting somatostatin analogue. N Engl J Med. 1986;315:663–666.
  7. Wynick D, Anderson JV, Williams SJ, Bloom SR. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS). Clin Endocrinol (Oxf). 1989;30:201–995, 385–388.
  8. Rinke A, Muller HH, Schade-Brittinger C. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the Group. J Clin Oncol. 2009;27:4656–4663.
  9. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–233.
  10. Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017;104:26–32.
  11. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer. 1997;79:830–834.
  12. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Clark Gamblin T, Turaga KK. Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. Ann Surg Oncol. 2014;21:240–247.
  13. Attanasio R, Mainolfi A, Grimaldi F, Cozzi R, Montini M, Carzaniga C, et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest. 2008;31:704–710.
  14. Sundstrom S, Bremnes RM, Kaasa S. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20:4665–4672.
  15. Iwasa S, Morizane C, Okusaka T. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010;40:313–318.
  16. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials. 1979;2:327–334.
  17. Sun W, Lipsitz S, Catalano P. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897–4904.
  18. Oberg K, Eriksson B. Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol. 1989;28:425–431.
  19. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol. 1989;7:865–868.
  20. Tiensuu Janson EM, Ahlstrom H, Andersson T, Oberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer. 1992;28a:1647–1650.
  21. Oberg K, Eriksson B, Janson ET. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion. 1994;55(suppl 3): 64–69.
  22. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–176.
  23. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–577.
  24. Vogl TJ, Naguib NNN, Zangos S. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Endocrinol 2009;72:517–528.
  25. Gupta S, Johnson MM, Murthy R. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–1602.
  26. Roche A, Girish BV, de Baere T. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology. 2004;51: 1751–1756.
  27. King J, Glenn D, Quinn R. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–929.
  28. Henn AR, Levine EA, McNulty W, Zagoria RJ. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol. 2003;181: 1005–1010.
  29. Gamblin TC, Christians K, Pappas SG. Radiofrequency ablation of neuroendocrine hepatic metastasis. Surg Oncol Clin N Am. 2011;20:273–279, vii–viii.
  30. Moreno A, Akcakanat A, Munsell MF. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008;15:257–266.
  31. Yao JC, Shah MH, Ito T. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523.
  32. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–977.
  33. Pavel ME, Hainsworth JD, Baudin E. Everolimus plus octreotide long-acting repeaТаблица for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005–2012.
  34. Yao JC, Phan A, Hoff PM. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26:1316–1323.
  35. Raymond E, Dahan L, Raoul JL. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–513.
  36. Kulke MH, Lenz HJ, Meropol NJ. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–3410.
  37. Cwikla JB, Sankowski A, Seklecka N. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21:787–794.
  38. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005;12:683–699.
  39. Strosberg JR, Wolin EM, Chasen B, Lu D. NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177(abstract). J Clin Oncol. 2016;34.
  40. Villard L, Romer A, Marincek N. Cohort study of somatostatin-BASED radiopeptide therapy with [90Y-DOTA]-[90Y-DOTA]-[177Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30: 1100–1106.
  41. Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh
  42. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589–597.
  43. Harris AG, Dorisio TM, Woltering EA. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel Digestive diseases and sciences. Dig Dis Sci. 1995;40:1464–1473.
  44. Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016;27:68–81.
  45. Haugvik SP, Hedenstrom P, Korsaeth E, Valente R, Hayes A, Siuka D, et al. Diabetes, smoking, alcohol use, and family history of cancer as risk factors for pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Neuroendocrinology. 2015;101: 133–142.
  46. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol. 1998;170:1315–1322.
  47. Khashab MA, Yong E, Lennon AM, Shin EJ, Amateau S, Hruban RH, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc. 2011;73:691–696.
  48. Gouya H, Vignaux O, Augui J. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol. 2003;181:987–992.
  49. Ichikawa T, Peterson MS, Federle MP. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology. 2000;216:163–171.
  50. Thoeni RF, Mueller-Lisse UG, Chan R. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology. 2000;214:483–490.
  51. Owen NJ, Sohaib SA, Peppercorn PD. MRI of pancreatic neuroendocrine tumours. Br J Radiol. 2001;74:968–973.
  52. Semelka RC, Custodio CM, Cem Balci N, Woosley JT. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging. 2000;11:141–148.
  53. Chang F, Chandra A, Culora G. Cytologic diagnosis of pancreatic endocrine tumors by endoscopic ultrasound-guided fine-needle aspiration: a review. Diagn Cytopathol. 2006;34:649–658.
  54. Rosch T, Lightdale CJ, Botet JF. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326:1721-1726.
  55. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19:829–837.
  56. Placzkowski KA, Vella A, Thompson GB, Grant CS, Reading CC, Charboneau JW, et al. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab. 2009;94:1069–1073.
  57. Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma–incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66:711–719.
  58. Fajans SS, Vinik AI. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am. 1989;18: 45–74.
  59. Boden G. Insulinoma and glucagonoma. Semin Oncol. 1987;14:253–262.
  60. Grunberger G, Weiner JL, Silverman R. Factitious hypoglycemia due to surreptitious administration of insulin. Diagnosis treatment and longterm followup. Ann Intern Med. 1988;108:252–257.
  61. Ferrer-Garcia JC, Iranzo Gonzalez-Cruz V, NavasDeSolis S, Civera-Andres M, Morillas-Arino C, Merchante-Alfaro A, et al. Management of malignant insulinoma. Clin Transl Oncol. 2013;15:725–731.
  62. Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg. 2006;93:264–275.
  63. Kahn CR, Rosen SW, Weintraub BD. Ectopic production of chorionic gonadotropin and its subunits by islet-cell tumors. A specific marker for malignancy. N Engl J Med. 1977;297:565–569.
  64. Alsever RN, Roberts JP, Gerber JG. Insulinoma with low circulating insulin levels: the diagnostic value of proinsulin measurements. Ann Intern Med. 1975;82:347–350.
  65. Bone HG 3rd. Diagnosis of the multiglandular endocrine neoplasias. Clin Chem. 1990;36:711–718.
  66. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–781.
  67. Ayav A, Bresler L, Brunaud L, Boissel P. Laparoscopic approach for solitary insulinoma: a multicentre study. Langenbecks Arch Surg. 2005;390:134–140.
  68. Finlayson E, Clark OH. Surgical treatment of insulinomas. Surg Clin North Am. 2004;84:775–785.
  69. Power L. A glucose-responsive insulinoma. JAMA. 1969;207:893–896.
  70. Maton PN. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Gastroenterol Clin North Am. 1989;18: 897–922.
  71. Holland J, Bast R, Morton D, eds. Cancer Medicine. 1997.
  72. Roth H, Thier S, Segal S. Zinc glucagon in the management of refractory hypoglycemia due to insulin-producing tumors. N Engl J Med. 1966;274: 493–497.
  73. Landau BR, Levine HJ, Hertz R. Prolonged glucagon administration in a case of hyperinsulinism due to disseminated islet cell carcinoma. N Engl J Med. 1958;259:286–288.
  74. Graber AL Jr, Williams D, Porte RH. Clinical use of diazoxide and mechanism for its hyperglycemic effects. Diabetes. 1966;15:143–148.
  75. Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer. 2005;104:264–272.
  76. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98–119.
  77. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996;75:53–63.
  78. Friesen SR. Tumors of the endocrine pancreas. N Engl J Med. 1982;306:580–590.
  79. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2:347–361.
  80. Levy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28:1075– 1081.
  81. Castro PG, de Leon AM, Trancon JG, Martinez PA, Alvarez Perez JA, Fernandez Fernandez JC, et al. Glucagonoma syndrome: a case report. J Med Case Rep. 2011;5:402.
  82. Higgins GA, Recant L, Fischman AB. The glucagonoma syndrome: surgically curable diabetes. Am J Surg. 1979;137:142–148.
  83. Weinel RJ, Neuhaus C, Stapp J. Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy. Ann Surg. 1993;218:640–645.
  84. Kirkwood KS, Debas HT. Neuroendocrine tumors: common presentations of uncommon diseases. Compr Ther. 1995;21:719–725.
  85. Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, et al. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Ann Surg Oncol. 2012;19:2295–2303.
  86. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96:175–184.
  87. Bloom SR, Polak JM. Glucagonoma syndrome. Am J Surg. 1987;82:25–36.
  88. Chu QD, Al-kasspooles MF, Smith JL, Nava HR, Douglass HO Jr, Driscoll D, et al. Is glucagonoma of the pancreas a curable disease? Int J Pancreatol. 2001;29:155–162.
  89. Krejs GJ, Orci L, Conlon JM. Somatostatinoma syndrome. Biochemical morphologic and clinical features. N Engl J Med. 1979;301:285–292.
  90. Harris GJ, Tio F, Cruz AB Jr. Somatostatinoma: a case report and review of the literature. J Surg Oncol. 1987;36:8–16.
  91. Doherty GM. Rare endocrine tumours of the GI tract. Best Pract Res Clin Gastroenterol. 2005;19:807– 817.
  92. Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015;13:78–108.
  93. Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res. 1999;18:13–22.
  94. Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg. 1994;31:77–156.
  95. Jensen RT, Gardner JD, Raufman JP. ZollingerEllison syndrome: current concepts and management. Ann Intern Med. 1983;98:59–75.
  96. Levy AD, Sobin LH. From the archives of the AFIP: gastrointestinal carcinoids: imaging features with clinicopathologic comparison. Radiographics. 2007;27:237–257.
  97. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg. 2003;237:650–657, discussion 7–9.
  98. Ellison EC, Carey LC, Sparks J. Early surgical treatment of gastrinoma. Am J Surg. 1987;82:17–24.
  99. McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology. 1980;79:1324–1331.
  100. Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in ZollingerEllison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). 2006;85:331–364.
  101. Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med. 1995;46:395–411.
  102. O’Toole D, Grossman A, Gross D. ENETS Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90:194–202.
  103. Gibril F, Reynolds JC, Doppman JL. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996;125:26–34.
  104. Zollinger RM, Ellison EC, Fabri PJ. Primary peptic ulcerations of the jejunum associated with islet cell tumors. Twenty-five year appraisal. Ann Surg. 1980;192:422–430.
  105. Bonfils S, Landor JH, Mignon M, Hervoir P. Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome. Ann Surg. 1981;194:692–697.
  106. Metz DC, Comer GM, Soffer E. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther. 2006;23:437–444.
  107. Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol. 2005;3:39–48.
  108. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635–644.
  109. Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244: 410–419.

522a. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol. 1999;17(2):615–630.

  1. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Surg. 1958;25:374–380.
  2. Kane MG, Dorisio TM, Krejs GJ. Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. N Engl J Med. 1983;309: 1482–1485.
  3. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res. 1998;17:389–400.
  4. Contessa JN, Griffith KA, Wolff E, Ensminger W, Zalupski M, Lawrence TS, et al. Radiotherapy for pancreatic neuroendocrine tumors. Int J Radiat Oncol Biol Phys. 2009;75:1196–1200.
  5. Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology. 2007;85:216–220.
  6. Kvols LK, Buck M, Moertel CG. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS). Ann Intern Med. 1987;107:201– 995, 162–168.
  7. Pavel ME, Baum U, Hahn EG. Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res. 2006;26:8–13.
  8. Schein P, Kahn R, Gorden P. Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature. Arch Intern Med. 1973;132:555–561.
  9. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189–1194.
  10. Cheng PN, Saltz LB. Failure to confi major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86:944–948.
  11. Gonzalez MA, Biswas S, Clifton L, Corrie PG. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer. 2003;89:455–456.
  12. Moertel CG, Lefkopoulo M, Lipsitz S. Streptozocindoxorubicin, streptozocin-fl ouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–523.
  13. Kouvaraki MA, Ajani JA, Hoff P. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–4771.
  14. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, et al. Oxaliplatin-fluoropyrimidine chemotherapy plus bevacizumab in advanced neuroendocrine tumors: an analysis of 2 phase II trials. Pancreas. 2016;45:1394–1400.
  15. Kulke MH, Stuart K, Enzinger PC. Phase II, study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401–406.
  16. Strosberg JR, Fine RL, Choi J. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268–275.
  17. Kulke MH, Niedzwiecki D, Foster NR. Randomized phase II study of everolimus versus everolimus plus bevacizumab in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET),CALGB 80701 (Alliance) (abstr). Oncol (suppl; abstr 4005). Abstract available online at http://meetinglibrary.asco.org/content/. Accessed on September 4, 2015.
  18. Dudney WC, Bodenner D, Stack BC Jr. Parathyroid carcinoma. Otolaryngol Clin North Am. 2010;43: 441–453, xi.
  19. Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo LO. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16:724–731.
  20. Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136:878–885.
  21. Lee PK, Jarosek SL, Virnig BA. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736– 1741.
  22. James BC, Aschebrook-Kilfoy B, Cipriani N, Kaplan EL, Angelos P, Grogan RH. The incidence and survival of rare cancers of the thyroid, parathyroid, adrenal, and pancreas. Ann Surg Oncol. 2016;23: 424–433.
  23. Arnold A, Shattuck TM, Mallya SM. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res. 2002;17(suppl 2):N30–N36.
  24. Carpten JD, Robbins CM, Villablanca A. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32:676–680.
  25. Shattuck TM, Valimaki S, Obara T. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722–1729.
  26. Howell VM, Haven CJ, Kahnoski K. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 2003;40: 657–663.
  27. Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2005;90:5015–5017.
  28. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004;89:5583–5591.
  29. Cryns VL, Thor A, Xu HJ. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med. 1994;330:757–761.
  30. Cryns VL, Rubio MP, Thor AD. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab. 1994;78:1320–1324.
  31. Haven CJ, van Puijenbroek M, Tan MH. Identifi tion of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf). 2007;67:370–376.
  32. Singh Ospina N, Sebo TJ, Thompson GB, Clarke BL, Young WF Jr. Prevalence of parathyroid carcinoma in 348 patients with multiple endocrine neoplasia type 1—case report and review of the literature. Clin Endocrinol (Oxf). 2014.
  33. Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg. 1991;15:738–744.
  34. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 1992;71:197–205.
  35. Givi B, Shah JP. Parathyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22:498–507.
  36. Wilkins BJ Jr, Lewis JS. Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol. 2009;3:140–149.
  37. Messerer CL, Bugis SP, Baliski C, Wiseman SM. Normocalcemic parathyroid carcinoma: an unusual clinical presentation. World J Surg Oncol. 2006;4:10.
  38. Sahasranam P, Tran MT, Mohamed H, Friedman TC. Multiglandular parathyroid carcinoma: a case report and brief review. South Med J. 2007;100:841– 844.
  39. Busaidy NL, Jimenez C, Habra MA. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26: 716–726.
  40. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol. 2001;2:347–354.
  41. Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86:485–493.
  42. Hara H, Igarashi A, Yano Y, Yashiro T, Ueno E, Aiyoshi Y, et al. Ultrasonographic features of parathyroid carcinoma. Endocr J. 2001;48:213–217.
  43. Sidhu PS, Talat N, Patel P, Mulholland NJ, Schulte KM. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol. 2011;21:1865–1873.
  44. Gao WC, Ruan CP, Zhang JC, Liu HM, Xu XY, Sun YP, et al. Nonfunctional parathyroid carcinoma. J Cancer Res Clin Oncol. 2010;136:969–974.
  45. Kassahun WT, Jonas S. Focus on parathyroid carcinoma. Int J Surg. 2011;9:13–19.
  46. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer. 1973;31:600–605.
  47. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Clin Pathol. 1993;17:820–829.
  48. Truran PP, Johnson SJ, Bliss RD, Lennard TW, Aspinall SR. Parafi omin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014;38:2845–2854.
  49. Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13:11–23.
  50. Betea D, Potorac I, Beckers A. Parathyroid carcinoma: challenges in diagnosis and treatment. Ann Endocrinol (Paris). 2015;76:169–177.
  51. Rubin MR, Silverberg SJ, D’Amour P, Brossard JH, Rousseau L, Sliney J Jr, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem. 2007;53:1470–1476.
  52. Caron P, Maiza JC, Renaud C, Cormier C, Barres BH, Souberbielle JC. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2009;70: 533–538.
  53. Cavalier E, Betea D, Schleck ML, Gadisseur R, Vroonen L, Delanaye P, et al. The third/second generation PTH assay ratio as a marker for parathyroid carcinoma: evaluation using an automated platform. J Clin Endocrinol Metab. 2014;99:E453–E457.
  54. Owen RP, Silver CE, Pellitteri PK. Parathyroid carcinoma: a review. Head Neck. 2011;33:429–436.
  55. Shane E, Bilezikian JP. Parathyroid carcinoma: a review of 62 patients. Endocr Rev. 1982;3:218–226.
  56. Sandelin K, Thompson NW, Bondeson L. Metastatic parathyroid carcinoma: dilemmas in management. Surgery. 1991;110:978–986, discussion 986–988.
  57. Hoelting T, Weber T, Werner J, Herfarth C. Surgical treatment of parathyroid carcinoma (review). Oncol Rep. 2001;8:931–934.
  58. Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–3686.
  59. Silverberg SJ, Rubin MR, Faiman C. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3803–3808.

 

 

 

 

 

 

11110077..ee1111

 

 

  1. de Papp AE, Kinder B, LiVolsi V. Parathyroid carcinoma arising from parathyroid hyperplasia: autoinfarction following intravenous treatment with pamidronate. Am J Surg. 1994;97:399–400.
  2. Szmuilowicz ED, Utiger RD. A case of parathyroid carcinoma with hypercalcemia responsive to cinacalcet therapy. Nat Clin Pract Endocrinol Metab. 2006;2(5):291–296.
  3. Vellanki P, Lange K, Elaraj D, Kopp PA, El Muayed
  4. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. J Clin Endocrinol Metab. 2014;99:387–390.
  5. Tong CV, Hussein Z, Noor NM, Mohamad M, Ng WF. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia. QJM. 2015;108:49–50.
  6. Nadarasa K, Theodoraki A, Kurzawinski TR, Carpenter R, Bull J, Chung TT, et al. Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma. Eur J Endocrinol. 2014;171:L7–L8.
  7. Karuppiah D, Thanabalasingham G, Shine B, Wang LM, Sadler GP, Karavitaki N, et al. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. Eur J Endocrinol. 2014;171:K1–K5.
  8. Tochio M, Takaki H, Yamakado K, Uraki J, Kashima M, Nakatsuka A, et al. A case report of 20 lung radiofrequency ablation sessions for 50 lung metastases from parathyroid carcinoma causing hyperparathyroidism. Cardiovasc Intervent Radiol. 2010;33:657–659.
  9. Artinyan A, Guzman E, Maghami E, Al-Sayed M, D’Apuzzo M, Wagman L, et al. Metastatic parathyroid carcinoma to the liver treated with radiofrequency ablation and transcatheter arterial embolization. J Clin Oncol. 2008;26:4039–4041.
  10. Bradwell AR, Harvey TC. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet. 1999;353:370–373.
  11. Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye B, et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab. 2004;89:3413–3420.
  12. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidismjaw tumor syndrome. J Clin Endocrinol Metab. 2004;89:96–102.
  13. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between a National Cancer Data Base Report The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86:1985–1995, 538–544.
Top.Mail.Ru